1-甲基-4-(戊-2-基)哌嗪 | 1119277-66-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-甲基-4-(戊-2-基)哌嗪
• 英文名称: 1-methyl-4-(pentan-2-yl)piperazine
• 英文别名: 1-methyl-4-pentan-2-ylpiperazine
• CAS: 1119277-66-5
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.298
• InChiKey: HPJYPDPTQDIPFP-UHFFFAOYSA-N

物化性质

• 沸点：
  207.8±8.0 °C(Predicted)
• 密度：
  0.879±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(戊-2-基)哌嗪 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 水 、 双(2-二苯基磷苯基)醚 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 生成 2-戊醇
  参考文献：
  名称：

  Hamid, M. Haniti S. A.; Allen, C. Liana; Lamb, Gareth W., Journal of the American Chemical Society, 2009, vol. 131, p. 1766 - 1774

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基哌嗪 、 2-戊醇 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 双(2-二苯基磷苯基)醚 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 24.17h， 以80%的产率得到1-甲基-4-(戊-2-基)哌嗪
  参考文献：
  名称：

  Hamid, M. Haniti S. A.; Allen, C. Liana; Lamb, Gareth W., Journal of the American Chemical Society, 2009, vol. 131, p. 1766 - 1774

  摘要：

  DOI：

文献信息

• POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
  申请人：ModernaTX, Inc.

  公开号：EP3896164A1

  公开（公告）日：2021-10-20

  The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.

  本发明涉及治疗法布里病的mRNA疗法。用于本发明的mRNA在体内给药时，编码人的α-半乳糖苷酶A（GLA）、其同工型、其功能片段和包含GLA的融合蛋白。本发明的mRNA优选封装在脂质纳米颗粒（LNPs）中，以便在给药时有效地传递到受试者的细胞和/或组织中。本发明的mRNA疗法可提高和/或恢复受试者体内不足的GLA表达和/或活性水平。本发明的mRNA疗法可进一步降低与受试者体内GLA活性不足有关的毒性代谢物，即Gb3和溶菌酶Gb3的水平。
• Sigma receptor binders
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US10954217B2

  公开（公告）日：2021-03-23

  Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, and neuropathic pain.

  本文特别提供了用于治疗癌症、神经系统疾病、戒酒、抑郁和焦虑以及神经性疼痛等疾病的化合物和方法。
• Heterocyclic compounds useful as aurora a selective inhibitors
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：US11384066B1

  公开（公告）日：2022-07-12

  Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.

  所提供的式 (I) 化合物或其药学上可接受的盐类可用于抑制 Aurora A 的活性和治疗由 Aurora A 介导的癌症。
• SMALL MOLECULE INHIBITORS OF EGFR AND PI3K
  申请人：The Regents of the University of Michigan

  公开号：US20190002460A1

  公开（公告）日：2019-01-03

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a pyrido-pyrimidin-amine structure, a thieno-pyrimidin-amine structure, a thiazolo-pyrimidin-amine structure, a furo-pyrimidin-amine structure, an oxazolo-pyrimidin-amine structure, a purin-amine structure, a pyrrolo-pyrimidin-amine structure, an amino-naphthyridine-carbonitrile structure, an amino-thieno-pyridine-carbonitrile structure, an amino-thiazo-pyridine-carbonitrile structure, an amino-furo-pyridine-carbonitrile structure, an amino-oxazolo-pyridine-carbonitrile structure, an amino-imidazo-pyridine-carbonitrile structure, or an amino-pyrrolo-pyridine-carbonitrile structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.
• SIGMA RECEPTOR BINDERS
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20190177301A1

  公开（公告）日：2019-06-13

  Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, and neuropathic pain.